How many shares will be issued under the grant and what percentage of the total outstanding shares does that represent?
Shares to be issued under the grant
- The Compensation Committee approved a grant of nonâqualified stock options that, when exercised, will allow the purchase of 181,450 shares of Viridian Therapeuticsâ common stock.
What percentage of the companyâs outstanding shares does this represent?
To express the grant as a percentage of the total outstanding shares, the following formula is used:
[
\text{Percentage} = \frac{\text{Shares in the grant}}{\text{Total outstanding shares}} \times 100\%
]
Plugâin the numbers:
[
\text{Percentage} = \frac{181,450}{\text{Total outstanding shares}} \times 100\%
]
However, the news release does not disclose Viridian Therapeuticsâ total number of outstanding shares.
Without that figure, the exact percentage cannot be calculated from the information provided.
How you could compute it if the outstandingâshare count were known
Example | Assumed Outstanding Shares | Calculation | Result |
---|---|---|---|
A | 10,000,000 | (\frac{181,450}{10,000,000} \times 100\%) | 1.81âŻ% |
B | 20,000,000 | (\frac{181,450}{20,000,000} \times 100\%) | 0.91âŻ% |
C | 5,000,000 | (\frac{181,450}{5,000,000} \times 100\%) | 3.63âŻ% |
Bottom line
- Shares to be issued: 181,450 shares.
- Percentage of total outstanding shares: Cannot be determined from the press release alone; you would need Viridian Therapeuticsâ current total outstanding share count (available from the companyâs most recent SEC filings, investor presentations, or other public disclosures) and then apply the formula above.
Other Questions About This News
What are the potential shortâterm and mediumâterm impacts on VRDNâs stock price and trading volume?
How does the Nasdaq Listing Rule 5635(c)(4) affect the timing or reporting of this grant?
Is the 181,450âshare grant consistent with the companyâs overall compensation philosophy and future hiring plans?
How might the grant affect the company's cash flow, tax expense, and earnings per share?
How does this compensation grant compare to prior issuances or similar grants at peer biotech companies?
What is the rationale behind using nonâqualified stock options rather than other equity awards?
Will the issuance be disclosed in the upcoming 10âK or 10âQ filing, and what regulatory filings are required?
What is the estimated dilution impact on existing shareholders from the 181,450 share option grant?
Is there any indication that this grant is part of a larger equity incentive plan or a oneâoff award?
What are the exercise prices and vesting schedules for the granted stock options?
Who are the four new employees receiving the options and what roles will they fill within the company?